Coston McIsaac & Partners’s Gilead Sciences GILD Stock Holding History

Coston McIsaac & Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Hold	119	–	–	﹤0.01%	526
2026 Q1	$16K	Hold	119	–	–	﹤0.01%	503
2025 Q4	$14K	Buy	119 +1	+0.8%	+$122	﹤0.01%	527
2025 Q3	$13K	Buy	118 +1	+0.9%	+$114	﹤0.01%	506
2025 Q2	$13K	Hold	117	–	–	﹤0.01%	491
2025 Q1	$13K	Buy	117 +1	+0.9%	+$103	﹤0.01%	462
2024 Q4	$10K	Buy	116 +1	+0.9%	+$90	﹤0.01%	479
2024 Q3	$9K	Buy	115 +1	+0.9%	+$76	﹤0.01%	514
2024 Q2	$7K	Buy	114 +2	+2%	+$133	﹤0.01%	519
2024 Q1	$8K	Buy	112 +1	+0.9%	+$77	﹤0.01%	507
2023 Q4	$9K	Buy	111 +1	+0.9%	+$78	﹤0.01%	485
2023 Q3	$8K	Buy	110 +1	+0.9%	+$77	﹤0.01%	495
2023 Q2	$8K	Buy	109 +1	+0.9%	+$80	﹤0.01%	532
2023 Q1	$9K	Buy	108 +1	+0.9%	+$83	﹤0.01%	500
2022 Q4	$9K	Buy	107 +1	+0.9%	+$79	﹤0.01%	510
2022 Q3	$6K	Buy	106 +1	+1%	+$63	﹤0.01%	483
2022 Q2	$7K	Buy	+105	New	+$6.5K	﹤0.01%	312

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coston McIsaac & Partners's GILD Position: Q2 2026 in Review

Coston McIsaac & Partners held its Gilead Sciences (GILD) position steady in Q2 2026 at 119 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

Coston McIsaac & Partners first reported a position in GILD in Q2 2022 and has held it in 17 quarters since. The position peaked at $16K in Q1 2026. 2,274 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Coston McIsaac & Partners held 119 shares of Gilead Sciences worth $15K as of Q2 2026.
Coston McIsaac & Partners left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #526 holding.
Coston McIsaac & Partners first reported a position in Gilead Sciences in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's Gilead Sciences position peaked at $16K in Q1 2026.
2,274 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.